Zynex (ZYXI) Expected to Announce Quarterly Earnings on Monday

Zynex (NASDAQ:ZYXI - Get Free Report) is projected to release its earnings data before the market opens on Monday, April 28th. Analysts expect Zynex to post earnings of ($0.24) per share and revenue of $30.83 million for the quarter. Zynex has set its Q1 2025 guidance at -0.300- EPS.Investors interested in registering for the company's conference call can do so using this link.

Zynex (NASDAQ:ZYXI - Get Free Report) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.02) earnings per share for the quarter, missing analysts' consensus estimates of $0.09 by ($0.11). Zynex had a return on equity of 13.05% and a net margin of 2.49%. The company had revenue of $45.98 million for the quarter, compared to analyst estimates of $53.65 million. During the same period in the previous year, the business posted $0.04 EPS. On average, analysts expect Zynex to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Zynex Trading Up 1.4 %

Shares of Zynex stock opened at $2.18 on Monday. The company has a current ratio of 3.94, a quick ratio of 3.15 and a debt-to-equity ratio of 1.66. The company has a fifty day simple moving average of $4.40 and a 200-day simple moving average of $6.84. The stock has a market cap of $65.89 million, a price-to-earnings ratio of 14.53 and a beta of 1.09. Zynex has a 12-month low of $1.93 and a 12-month high of $12.19.

Insider Activity at Zynex

In other Zynex news, CFO Daniel J. Moorhead sold 10,000 shares of Zynex stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $7.15, for a total value of $71,500.00. Following the transaction, the chief financial officer now directly owns 10,050 shares in the company, valued at approximately $71,857.50. The trade was a 49.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 49.28% of the stock is owned by insiders.

Analysts Set New Price Targets

ZYXI has been the subject of several research analyst reports. Royal Bank of Canada restated a "sector perform" rating on shares of Zynex in a research note on Tuesday, April 15th. LADENBURG THALM/SH SH cut Zynex from a "buy" rating to a "neutral" rating in a research report on Wednesday, March 12th. Finally, HC Wainwright dropped their price target on Zynex from $17.00 to $15.00 and set a "buy" rating on the stock in a research note on Wednesday, March 12th.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.